Hyderabad, March 14,2014: According to the US Food and Drug Administration, the Hyderabad-based company was recalling 58,656 bottles of the drug due to a microbial contamination.
The recall has been classified as ‘Class II’, which, as per FDA norms, is not a serious problem, with only a remote chance of severe adverse consequences from contamination in the product.
A Dr Reddy’s spokesperson said that it was a voluntary recall and that there was no financial implication.
On the Bombay Stock Exchange, the Dr Reddy’s scrip ended Thursday at Rs. 2,734, up 1.63 per cent.
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…